“In the wake of the failed IMS III Study, a NINDS-funded randomized controlled trial, there will be some physicians who will question the benefit of mechanical thrombectomy,” said Vitor Mendes Pereira, M.D., MSc, STAR Principal Investigator, Head of Interventional Neuroradiology, University Hospital of Geneva, Switzerland. “The results of the STAR prospective, multi-center clinical study demonstrate that mechanical thrombectomy is both safe and effective for the treatment of acute ischemic stroke when treating the right patients, in comprehensive stroke centers, with the Solitaire FR device.”The results of the STAR clinical study indicate that treatment with the Solitaire FR device in intracranial anterior circulation occlusions is associated with:
- Low risk of clinically relevant procedural and device-related complications;
- High rates of revascularization (TICI ≥2b) and Good Clinical Outcomes (mRS 0-2); and
- Low mortality at 90 days.
About CovidienCovidien is a leading global healthcare products company that creates innovative medical solutions for better patient outcomes and delivers value through clinical leadership and excellence. Covidien manufactures, distributes and services a diverse range of industry-leading product lines in three segments: Medical Devices, Pharmaceuticals and Medical Supplies. With 2012 revenue of $11.9 billion, Covidien has 43,000 employees worldwide in 70 countries, and its products are sold in over 140 countries. Please visit www.covidien.com to learn more about our business. 1. Wechsler, L.R., Intravenous Thrombolytic Therapy for Acute Ischemic Stroke . New England Journal of Medicine, 2011. 364(22): p. 2138‐2146. 2. Writing Group Members, et al., Heart Disease and Stroke Statistics—2013 Update . Circulation, 2012. 127(1): p. e6‐e245. 3. Saver, J.L., Time Is Brain—Quantified . Stroke, 2006. 37(1): p. 263‐266. 4. Donnan, G.A., et al., Stroke. The Lancet, 2008. 371(9624): p. 1612‐1623.